Dabrafenib for treatment of BRAF-mutant melanoma

Pharmacogenomics and Personalized Medicine

Volumn 7, Issue 1, 2013, Pages 21-29

  Kainthla, Radhika ^a   Kim, Kevin B ^b   Falchook, Gerald S ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Department of Melanoma Medical Oncology ^*  (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Dabrafenib; Metastatic melanoma; V600E BRAF mutation

Indexed keywords

B RAF KINASE; DABRAFENIB; DACARBAZINE; IMMUNOMODULATING AGENT; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TRAMETINIB;

ARTHRALGIA; BRAF GENE; BRAIN METASTASIS; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CHORIORETINOPATHY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; FEVER; GENE FREQUENCY; GENE MUTATION; HEADACHE; HUMAN; HYPERKERATOSIS; IMMUNOMODULATION; KERATOACANTHOMA; MELANOMA; METASTASIS; MONOTHERAPY; NEUTROPENIA; PROGRESSION FREE SURVIVAL; REVIEW; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME;

EID: 84891681416     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S37220     Document Type: Review

References (59)

1. American Cancer Society. Cancer Facts and Figures 2013. Atlanta, GA: American Cancer Society; 2013.
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975_2009_pops09/. Accessed October 9, 2013.
3. Balch CM, Gershenwald JE, Soong S-J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36): 6199-6206.
4. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res. 2000;19(1):21-34.
5. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7): 2105-2116.
6. Schwartzentruber DJ, Lawson DH, Richards JM, et al. Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119-2127.
7. Guirguis LM, Yang JC, White DE, et al. Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother. 2002;25(1):82-87.
8. Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol. 2004;22(11):2101-2107.
9. Seigler HF, Lucas VS, Pickett NJ, Huang AT. DTIC, CCNU, bleomycin, and vincristine in metastatic melanoma. Cancer. 1980;46(11): 2346-2348.
10. Punt CJA, van Herpen CML, Jansen RLH, Vreugdenhil G, Muller EW, de Mulder PH. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon α for metastatic melanoma: a multicentre phase II study. Br J Cancer. 1997;76(2): 266-269.
11. Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008;26(35):5748-5754.
12. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy for metastatic melanoma: results from a Phase III randomized trial. J Clin Oncol. 2002;20(8):2045-2052.
13. Shinozaki M, Fujimoto A, Morton DL, Hoon DS. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res. 2004;10(5):1753-1757.
14. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251-263.
15. Goel VK, Lazar AJF, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS, and PTEN in rimary cutaneous melanoma. J Invest Dermatol. 2006;126(1):154-160.
16. Hersh EM, O'Day SJ, Powderly J, et al. A Phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs. 2001;29(3): 489-498.
17. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of the singleagent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167-3175.
18. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
19. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-133.
20. Hamid O, Robert C, Daud D, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2): 134-144.
21. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J. 1995;9(9): 726-735.
22. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signaling pathways in cancer. Oncogene. 2007;26(22):3279-3290.
23. Fang JY, Richardson BC. The MAPK signaling pathways and colorectal cancer. Lancet Oncol. 2005;6(5):322-327.
24. Kalady MF, Dejulius KL, Sanchez JA, et al. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum. 2012;55(2):128-133.
25. Frasca F, Nucera C, Pellegriti G, et al. BRAF (V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer. 2008;15(2):191-205.
26. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239-1246.
27. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
28. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855-867.
29. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A. 2008;105(8):3041-3046.
30. Lee JT, Li L, Brafford PA, et al. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res. 2010;23(6):820-827.
31. V600E mutation. Mol Cancer Ther. 2009;12 Suppl 1: Abstr B88.
32. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastaese, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379(9829):1893-1901.
33. Hauschild A, Grob J, Dimidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, Phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-365.
34. Hauschild A, Grob J, Dimidov LV, et al. An update on BREAK-3, a Phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). Poster 9013 presented at the 49th annual meeting of the American Society of Clinical Oncology, Chicago, IL, May 31 to June 4, 2013.
35. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet. 2012;13(11):1087-1095.
36. Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med. 2011;364(8):772-774.
37. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973-977.
38. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18(6): 683-695.
39. Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012;11(4):909-920.
40. Johnnessen CM, Boehm JS, Kim SY. COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468(7326):968-972.
41. Dumaz N, Hayward R, Martin J, et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 2006;66(19): 9483-9491.
42. Poulikakos PI, Persaud Y, Janakirman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480(7377):387-390.
43. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694-1703.
44. Janku F, Lee JJ, Tsimberidou AM, et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One. 2011;6(7):e22769.
45. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: Variations on a theme. Oncogene. 2008;27(41):5497-5510.
46. Mendoza MC, Er EE, Blenis J. The RAS-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011; 36(6):320-328.
47. Sanchez-Hernandez I, Baquero P, Calleros L, Chiloeches A. Dual inhibition of (V600E) BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism. Cancer Lett. 2012;314(2):244-255.
48. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer immune evasion in human melanoma cells. J Exp Med. 2006;203(7):1651-1656.
49. Hong DS, Vence L, Falchook GS, et al. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res. 2012;18(8):2326-3715.
50. Weichsel R, Dix C, Woolridge L, et al. Profound inhibition of antigenspecific T-cell effector functions by dasatinib. Clin Cancer Res. 2008;14(8):2484-2491.
51. Zhao W, Gu YH, Song R, Qu BQ, Xu Q. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia. 2008;22(6):1226-1233.
52. Wilmott JS, Long GV, Howie JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012;18(5):1386-1394.
53. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013;368(14):1365-1366.
54. Straussman R, Morikawa T, Shee K, et al. Tumor micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500-504.
55. Wilson TR, Fridlyand J, Yan Y, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487(7408):505-509.
56. Puri N, Ahmed S, Janamanchi V, et al. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res. 2007;13(7):2246-2253.
57. US Food and Drug Administration. Dabrafenib. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm354477.htm. Accessed October 9, 2013.
58. National Institutes of Health. Dabrafenib. Available from: http://www.clinicaltrials.gov/ct2/results?term=dabrafenib&search=search. Accessed November 7, 2013.
59. Girotti MR, Marais R. Déjà vu: EGF receptors drive resistance to BRAF inhibitors. Cancer Discov. 2013;3(5):487-490.